Welcome to our dedicated page for Immuneering news (Ticker: IMRX), a resource for investors and traders seeking the latest updates and insights on Immuneering stock.
Immuneering Corporation reports clinical oncology developments centered on Deep Cyclic Inhibitors, a category of cancer medicines the company is developing for durability, tolerability and combinability. Its lead product candidate, atebimetinib (IMM-1-104), is an oral, once-daily Deep Cyclic Inhibitor of MEK being studied across MAPK pathway-driven tumors, including pancreatic cancer.
Recurring updates include survival and safety data from atebimetinib in combination with modified gemcitabine/nab-paclitaxel in first-line pancreatic cancer, molecular and circulating tumor DNA analyses tied to MAPK resistance mechanisms, and presentations at oncology meetings such as ASCO and AACR. Company news also covers financial results, R&D spending, pipeline strategy, regulatory-readiness activities and healthcare-conference presentations.
Immuneering Corporation (Nasdaq: IMRX) announced its lead program IMM-1-104 at the AACR special conference, showcasing promising preclinical data. The research indicates that IMM-1-104 demonstrates efficacy across various RAS mutant cancer models, regardless of mutation type. The trial aims to explore universal-RAS therapy, targeting patients with advanced solid tumors harboring RAS mutations. Key findings include responses from 132 tumor models, with at least one response observed for each RAS mutation tested. The Phase 1/2a trial is currently enrolling patients.
Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology firm, announced participation in two investor conferences in March. The Cowen 43rd Annual Health Care Conference will feature a panel discussion on March 7, while the Oppenheimer 33rd Annual Healthcare Conference will include a virtual presentation on March 14. Management, including Co-Founder and CEO Ben Zeskind, will discuss the company’s pipeline and business strategy. Immuneering is focused on developing a universal-RAS therapy, with its lead product candidate, IMM-1-104, currently in a Phase 1/2a study targeting advanced solid tumors with RAS mutations.
Immuneering Corporation (Nasdaq: IMRX) announced it will release its fourth-quarter and full-year financial results for 2022 on March 6, 2023, after market close. Following the announcement, management will host a conference call at 4:30 p.m. ET to discuss the results. The company is focused on developing a universal-RAS therapy aimed at treating cancer patients, with its lead product candidate, IMM-1-104, currently in Phase 1/2a studies. Immuneering also has a significant pipeline, including the accelerated development program IMM-6-415 for RAS mutation patients.
Immuneering Corporation (Nasdaq: IMRX), a clinical stage biopharmaceutical company, announced its participation in the Guggenheim’s 2023 Oncology Conference. The company aims to develop treatments for patients with solid tumors caused by RAS mutations and other MAPK pathway events.
Co-Founder and CEO Ben Zeskind will discuss the company’s pipeline, platform, and business strategy during a fireside chat on February 9, 2023, from 3:20 to 3:45 PM ET. The presentation will be available for live streaming and archived for 30 days on Immuneering's website.
Immuneering Corporation (Nasdaq: IMRX) has initiated its Phase 1/2a clinical trial for IMM-1-104, a novel treatment targeting RAS mutations in solid tumors. The first patient was dosed on November 21, following IND clearance in late September. This trial aims to assess safety, tolerability, and preliminary efficacy in approximately 42 patients across five U.S. sites. IMM-1-104 employs a unique approach of deep cyclic inhibition of the MAPK pathway, potentially offering new therapeutic options for patients with advanced RAS mutant solid tumors.
Immuneering Corporation (Nasdaq: IMRX) has reported promising preclinical data for IMM-6-415, aimed at treating RAF and RAS mutant tumors. The data, presented at the SITC 37th Annual Meeting, shows that IMM-6-415 can operate effectively as a monotherapy and enhance the activity of immune checkpoint inhibitors. It demonstrates a uniquely short half-life, offering an accelerated dosing cadence compared to IMM-1-104. The company anticipates submitting an IND for IMM-6-415 in Q4 2023, with early studies indicating a significant therapeutic potential against hard-to-treat solid tumors.
Immuneering Corporation (Nasdaq: IMRX) has commenced recruiting for a Phase 1/2a clinical trial of IMM-1-104, targeting advanced solid tumors with RAS mutations. The first patient is expected to be dosed this quarter. Additionally, promising preclinical data on its second drug, IMM-6-415, was presented at the SITC meeting. Financially, the company reported cash and equivalents of $117.2 million, expected to last into Q3 2024. However, R&D expenses grew to $9.4 million from $6.2 million year-over-year, contributing to a net loss of $12.8 million for Q3 2022.
Immuneering Corporation (Nasdaq: IMRX) announced participation in three investor conferences in November 2022 to discuss its pipeline and business strategy. CEO Ben Zeskind and CSO Brett Hall will present at the Jefferies London Healthcare Conference on November 15, the Piper Sandler Healthcare Conference on November 29, and the Evercore ISI HealthCONx Conference on December 1. The company is advancing its lead candidate, IMM-1-104, currently in a Phase 1/2a trial for tumors with RAS mutations, aiming for targeted cancer treatment.
Immuneering Corporation (Nasdaq: IMRX) has appointed Leah R. Neufeld as Chief People Officer, a newly created position, effective immediately. Neufeld brings extensive experience from her previous roles at Luzsana Biotechnology and Prevail Therapeutics. CEO Ben Zeskind emphasized her leadership skills and expertise in enhancing company culture and attracting top talent. Immuneering focuses on developing medicines for patients with solid tumors driven by RAS mutations and MAPK pathway activations, leveraging its proprietary bioinformatics platform.
Immuneering Corporation (Nasdaq: IMRX) announced it will present data on its second program, IMM-6-415, at the 37th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) from November 8-12, 2022, in Boston. The poster presentation, titled Cyclic disruption of the mitogen-activated protein kinase (MAPK) pathway by the dual MEK inhibitor, IMM-6-415, highlights its potential in enhancing PD1 and CTLA4 checkpoint blockade for RAS mutant tumors. IMM-6-415 is a third-generation dual MEK inhibitor aimed at improving cancer therapies for patients with solid tumors driven by RAS mutations.